Breast Cancer Prognosis

Using PrognostiCheck®

www.ipgdx.com
PrognostiCheck® uses phase angle from impedance analysis
to detect the presence and severity of breast cancer, the
effectiveness of treatment and survival of breast cancer
patients who have the disease.

www.ipgdx.com
In a recent study of 259 breast cancer patients, 81 that were
newly diagnosed, 178 that had received prior treatment 56
with stage - I disease at diagnosis, 110 with stage - II, 46 with
stage - III and 34 with stage - IV.
http://www.virtualcancercentre.com/uploads/VMC/TreatmentImages/1247_Breast_Mid.jpg

www.ipgdx.com
Their ages ranged from 25 to 74
years old. The median phase angle
was 5.6 degrees.

www.ipgdx.com
 Patients with phase angle less
than or equal to 5.6° had a
median survival of only 23.1
months, while those greater
than 5.6° had 49.9 months.
http://www.virtualmedicalcentre.com/uploads/VMC/DiseaseImages/1250_Breast_LCIS_Med.jpg

www.ipgdx.com
PrognostiCheck® is a scoring system that
interprets a measured electrical value that
illustrates the health of the cell membrane.
It can be used to provide critically important
information to patients, their families and physicians
on survival in breast cancer and all other diseases.

www.ipgdx.com
The measurement of phase angle includes the
combined effects of the body’s fluids and cells
specifically the cellular membranes of the
human body.
By measuring these values PrognostiCheck®
reports information heretofore not available to
patients, families and their physicians.

www.ipgdx.com
Lower phase angle values indicate illnesses by seeing
cell death or decreased cell integrity, while higher
phase angle values indicate more intact cell
membranes and a healthier person.
http://graphics8.nytimes.com/images/2007/08/01/health/adam/9294.jpg

www.ipgdx.com
 http://www.medindia.net/patients/patientInfo/images/Breast_cancer.gif

In breast cancer the severity of the disease can be seen

and reported by PrognostiCheck® and guide the
patient to the level of care they need sooner and easier.

www.ipgdx.com
The PrognostiCheck® results come from a simple
noninvasive test that is quickly done has no side
effects and is easily repeated to show change over
time.

www.ipgdx.com
It is especially sensitive to changes and precise
with nearly perfect test re-test reliability (0.98
out of 1).
The device used for the test is an FDA 510(k)
approved Class II medical instrument.

www.ipgdx.com
 Breast Cancer Prognosis
Using PrognostiCheck®
By IPGDx, LLC
www.ipgdx.com
michaealsinger@ipgdx.com
jdkutzko@ipgdx.com
www.ipgdx.com